603130-13-8

Basic information

• Product Name: (2S,5R)-5-[(tert-Butoxycarbonyl)aMino]tetrahydro-2H-pyran-2-carboxylic Acid
• Synonyms: (2S,5R)-5-[(tert-Butoxycarbonyl)aMino]tetrahydro-2H-pyran-2-carboxylic Acid;(2S,5R)-5-Boc-aMino-tetrahydropyran-2-carboxylic acid;(2S,5R)-5-{[(tert-butoxy)carbonyl]amino}oxane-2-carboxylic acid;trans-5-(Boc-amino)-tetrahydro-pyran-2-carboxylic acid
• CAS NO: 603130-13-8
• Molecular Formula: C₁₁H₁₉NO₅
• Molecular Weight: 245.27226
• Product Categories: Heterocycles, Miscellaneous Reagents
• Mol File: 603130-13-8.mol

Chemical Properties

• Boiling Point: 413.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.57±0.40(Predicted)
• CAS DataBase Reference: (2S,5R)-5-[(tert-Butoxycarbonyl)aMino]tetrahydro-2H-pyran-2-carboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5R)-5-[(tert-Butoxycarbonyl)aMino]tetrahydro-2H-pyran-2-carboxylic Acid(603130-13-8)
• EPA Substance Registry System: (2S,5R)-5-[(tert-Butoxycarbonyl)aMino]tetrahydro-2H-pyran-2-carboxylic Acid(603130-13-8)

Safety Data

• Hazardous Substances Data: 603130-13-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,5R)-5-[(tert-Butoxycarbonyl)amino]tetrahydro-2H-pyran-2-carboxylic Acid is used as a synthetic intermediate for the development of novel tetrahydropyran-based compounds with potential anti-gram-positive activity. Its unique structure allows for the creation of new molecules that can target and inhibit specific bacterial enzymes, offering a promising avenue for the development of new antibiotics to combat drug-resistant gram-positive bacteria.
Additionally, (2S,5R)-5-[(tert-Butoxycarbonyl)amino]tetrahydro-2H-pyran-2-carboxylic Acid is used as a building block in the synthesis of novel tetrahydropyran-based dipeptide isoster compounds. These isosteres can potentially mimic the structure and function of natural peptides, leading to the development of new drugs with improved pharmacological properties, such as enhanced stability, bioavailability, and selectivity.

Upstream product

• 132375-36-1 6-O-(tert-butyldimethylsilyl)-1,5-anhydro-2,3-dideoxy-D-erythro-hex-2-enitol 
• 149342-25-6 ((2R,3S)-3-acetoxy-3,6-dihydro-2H-pyran-2-yl)methyl acetate 
• 125901-90-8 (2R,3S)-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-ol 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 199801-81-5 N-((3R,6S)-6-(((tert-butyldimethylsilyl)oxy)methyl)-3,6-dihydro-2H-pyran-3-yl)-2,2,2-trichloroacetamide 
• 199801-85-9 O-[(2R,3S)-2-(tert-butyldimethylsilyloxymethyl)-3,6-dihydro-2H-pyran-3-yl]trichloroethanecarboximidate 
• 603130-11-6 (2S,5R)-5-[(tert-butoxycarbonyl)amino]-2-[(tert-butyldimethylsilanyloxy)methyl]-2,5-dihydro-6H-pyran 
• 2873-29-2 D-glucal triacetate 

Downstream Products

• 1292819-37-4 benzyl ((3R,6S)-6-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)acetyl)tetrahydro-2H-pyran-3-yl)carbamate 
• 1398570-05-2 Methyl 2,6-anhydro-5-{[(benzyloxy)carbonyl]amino}-3,4,5-trideoxy-L-erythro-hexonate 
• 749175-42-6 (2S,5R)-5-Amino-tetrahydro-pyran-2-carboxylic acid 

Relevant articles and documents

Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity

There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential

TRICYCLIC ANTIBIOTICS

Compounds of formula (I), wherein A1 represents -0-, -S- or -CH2-; A2 represents -CH2- or -0-; A3 represents C3-C8cycloalkylene; saturated or unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, which group A3 is unsubstituted or substituted; A4 represents C1-C4alkylene, -C(=0)-; G represents aryl or heteroaryl, which is unsubstituted or substituted; X1 represents a nitrogen atom or CR1; R1 represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom; m is 0 or 1; n is 1; the -(CH2)n- group is unsubstituted or substituted; p is 0 or 1; or pharmaceutically acceptable salts thereof are valuable for use as a medicament for the treatment of bacterial infections.

NEW SYNTHETIC INTERMEDIATES FOR MANUFACTURING ANTIBIOTICS

The invention relates to a process for manufacturing antibiotic compounds of formula (A1) wherein each of R5 and R6 represents independently H or D, Y represents CH or N, Z represents O, S or CH2, and A represents CH2

AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans.

Synthesis of novel tetrahydropyran-based dipeptide isosters by overman rearrangement of 2,3-didehydroglycosides

Differently functionalized tetrahydropyran-based dipeptide isosters have been efficiently synthesized from 3,4,6-tri-Oacetyl-D-glucal. Analogues of the hsp65 p2-13 epitope of Mycobacterium tuberculosis and Mycobacterium leprae were prepared by replacement of the Ala-Tyr or Glu-Glu moiety in the native dodecapeptide with the prepared dipeptide isosters. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003).